Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content and blocking access to the ClinicalTrials.gov entry; as a result, the detailed study information is no longer visible on the page.SummaryDifference19%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing v3.6.5, indicating a small system update with no changes to the study details.SummaryDifference0.1%

- Check48 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor internal update to the page's metadata or structure rather than content changes to the study details.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4. This indicates a minor page update without changes to substantive content.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision updated to v3.6.3, signaling a minor page update. The content and study details remain unchanged.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page's revision metadata was updated to v3.6.2. The previous revision reference v3.6.0 was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.